Pancreatic Cancer Research

ResearcherUniversity Hospital in HalleActive in the last 2 years

Jonas Rosendahl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4513-0506; OpenAlex author ID A5056862255. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 0, last author 4)
Trials
1
Grants
0
Labs led
1
Collaborators
56
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper, 1 trial · 2025: 2 papers · 2026: 2 papers

Papers 15

  1. Pain profiles in pancreatic cancer and chronic pancreatitis: a multicenter cross-sectional analysis. Co-author DOI 10.3389/fpain.2026.1903789↗
  2. Widespread Hyperalgesia Predicts Mortality in Pancreatic Adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353594↗
  3. Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017. Co-author DOI 10.1002/cam4.71248↗
  4. Pancreatic adenocarcinoma patients with pain have abnormal central pain processing. Co-author DOI 10.1016/j.pan.2025.04.010↗
  5. Induction of oxidative- and endoplasmic-reticulum-stress dependent apoptosis in pancreatic cancer cell lines by DDOST knockdown. Last author DOI 10.1038/s41598-024-68510-8↗
  6. Body composition parameters predict survival in pancreatic cancer-A retrospective multicenter analysis. Last author DOI 10.1002/ueg2.12489↗
  7. Gender-specific changes of the gut microbiome correlate with tumor development in murine models of pancreatic cancer. Last author DOI 10.1016/j.isci.2023.106841↗
  8. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta… Co-author DOI 10.3390/cancers13174326↗
  9. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  10. The quality of pain management in pancreatic cancer: A prospective multi-center study. Last author DOI 10.1016/j.pan.2020.08.017↗
  11. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  12. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  13. [Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer?] Co-author DOI 10.1055/s-0043-118042↗
  14. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-310049↗
  15. Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis. Co-author DOI 10.1097/mpa.0000000000000573↗

Trials 1

  1. Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR) Study chair NCT06328101↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marko Damm · 9 shared papers, 2020–2026 · strength 1.62
  2. Patrick Michl · 8 shared papers, 2017–2025 · strength 1.25
  3. Sebastian Krug · 4 shared papers, 2021–2025 · strength 0.77
  4. Anna Evans Phillips · 3 shared papers, 2025–2026 · strength 0.75
  5. Dhiraj Yadav · 3 shared papers, 2025–2026 · strength 0.75
  6. Asbjørn Mohr Drewes · 3 shared papers, 2025–2026 · strength 0.75
  7. Vikesh K. Singh · 3 shared papers, 2025–2026 · strength 0.75
  8. Mahya Faghih · 3 shared papers, 2025–2026 · strength 0.75
  9. Søren Schou Olesen · 3 shared papers, 2025–2026 · strength 0.75
  10. Daniel A. Laheru · 3 shared papers, 2025–2026 · strength 0.75
  11. Marie-Theres Kassik · 2 shared papers, 2026 · strength 0.52
  12. Sophie Rauschenberg · 2 shared papers, 2026 · strength 0.52
  13. Lei Zheng · 2 shared papers, 2025–2026 · strength 0.49
  14. Julian Cardinal von Widdern · 1 shared trial, 2024 · strength 0.42
  15. Cecilie Siggaard Knoph · 1 shared trial, 2024 · strength 0.42
  16. Ivonne Regel · 1 shared trial, 2024 · strength 0.42
  17. Karri Kasse · 1 shared trial, 2024 · strength 0.42
  18. John A. G. Moir · 3 shared papers, 2020 · strength 0.27
  19. Maximilian Weniger · 3 shared papers, 2020 · strength 0.27
  20. Stephan Schorn · 3 shared papers, 2020 · strength 0.27
  21. Guralp Onur Ceyhan · 3 shared papers, 2020 · strength 0.27
  22. Heidi Griesmann · 2 shared papers, 2017–2023 · strength 0.24
  23. Richard Böhme · 1 shared paper, 2024 · strength 0.22
  24. Andrew Derek Hopper · 1 shared paper, 2023 · strength 0.17
  25. Mustafa Jalal · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.